Triet Nguyen

Triet Nguyen

Auto-generated profile, based on publicly available information

Triet Nguyen

Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Baltimore, School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
XWXing Wang
Xing Wang
NRNatasha Raman
Natasha Raman
GLGhali Lemtiri-Chlieh
Ghali Lemtiri-Chlieh
JCJinhee Chang
Jinhee Chang
SJShreya Jagtap
Shreya Jagtap
HWHailun Wang
Hailun Wang
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.

26 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TNTriet Nguyen
Triet Nguyen
FCFrancesca Anna Carrieri
Francesca Anna Carrieri
NKNick Konidaris
Nick Konidaris
ALAudrey Lafargue
Audrey Lafargue
JCJinhee Chang
Jinhee Chang
PTPhuoc Tran
Phuoc Tran
Most patients with lung squamous cell carcinoma (LSCC) undergo chemotherapy, radiotherapy, and adjuvant immunotherapy for locally advanced disease. The efficacy of these treatments is still limited because of dose-limiting toxicity or locoregional recurrence. New combination approaches and targets such as actionable oncogenic drivers are needed to advance treatment options for patients with LSCC. Moreover, other options for chemotherapy-ineligible patients are limited. As such, there is a critical need for the development of selective and potent chemoradiosensitizers for locally advanced LSCC. In this study, we investigated inhibiting TRAF2- and NCK-interacting protein kinase (TNIK), which is amplified in 40% of patients with LSCC, as a strategy to sensitize LSCC tumors to chemotherapy and radiotherapy. Employing a range of human LSCC cell lines and the TNIK inhibitor NCB-0846, we investigated the potential of TNIK as a chemo- and radiosensitizing target with in vitro and in vivo preclinical models. The combination of NCB-0846 with cisplatin or etoposide was at best additive. Interestingly, pre-treating LSCC cells with NCB-0846 prior to ionizing radiation (IR) potentiated the cytotoxicity of IR in a TNIK-specific fashion. Characterization of the radiosensitization mechanism suggested that TNIK inhibition may impair the DNA damage response and promote mitotic catastrophe in irradiated cells. In a subcutaneous xenograft in vivo model, pretreatment with NCB-0846 significantly enhanced the efficacy of IR and caused elevated necrosis in TNIKhigh LK2 tumors but not TNIKlow KNS62 tumors. Overall, these results indicate that TNIK inhibition may be a promising strategy to increase the efficacy of radiotherapy in patients with LSCC with high TNIK expression.

2 September 2026
Verified
Other
Open access
DCDipanwita Dutta Chowdhury
Dipanwita Dutta Chowdhury
EIEddie L. Imada
Eddie L. Imada
NKNick Konidaris
Nick Konidaris
JCJinhee Chang
Jinhee Chang
ACAaron Chan
Aaron Chan
CHChristine L. Hann
Christine L. Hann
Small cell lung cancer (SCLC) is characterized by early metastasis, intrinsic chemoradiation resistance, and tumor recurrence. Besides the lack of potentially targetable oncogenic drivers, therapeutic advancements are also hindered by the scarcity of surgically resected tissue specimens ideal for profiling studies. We used patient-derived xenografts (PDX) to model SCLC chemoradiation resistance and identified chemoradiation resistance candidate genes using RNA sequencing. Additionally, we used human SCLC cell lines to confirm our in vivo results and delineate the underlying mechanism. Transcriptome profiling showed that the Traf2- and Nck-interacting kinase (TNIK) gene was consistently upregulated in an array of SCLC PDXs exposed to chemoradiation compared with monotherapy, which is consistent with previous observations of TNIK amplification in human samples. Genetic depletion (P < 0.01) or pharmacologic inhibition (P < 0.0001) of TNIK reduced in vitro clonogenic survival of TNIKhigh SCLC cells and promoted sensitivity to chemoradiation. In vivo, pharmacologic inhibition of TNIK enhanced chemoradiation sensitivity (P < 0.0001) of the H446 cell line–derived xenograft (CDX) in NOD-SCID mice. Furthermore, pharmacologic inhibition of TNIK in vivo demonstrated sensitivity (P < 0.0001) to chemoradiotherapy (CRT) in LX33 PDX. These results indicate that TNIK plays a role in conferring resistance to chemoradiation in SCLC cell lines and in vivo in SCLC CDX and PDX models. Delineating the mechanism behind radiosensitization suggested that TNIK inhibition may impair the DNA damage response in irradiated cells. Collectively, these findings suggest that TNIK may be a promising therapeutic target in limited-stage SCLC and support further investigation of TNIK inhibition in combination with standard CRT.

2 September 2026
Verified
Other
Open access
DCDipanwita Dutta Chowdhury
Dipanwita Dutta Chowdhury
EIEddie L. Imada
Eddie L. Imada
NKNick Konidaris
Nick Konidaris
JCJinhee Chang
Jinhee Chang
ACAaron Chan
Aaron Chan
CHChristine L. Hann
Christine L. Hann
Supplementary Figure S7 shows the activation status of DDR proteins (yH2AX, ATM/p-ATM, Chk2/p-Chk2) in TNIK-overexpressing and mCherry-overexpressing (control) DMS114 cells post radiation (6 Gy), as determined by immunoblotting.

2 September 2026
Verified
Other
Open access
DCDipanwita Dutta Chowdhury
Dipanwita Dutta Chowdhury
EIEddie L. Imada
Eddie L. Imada
NKNick Konidaris
Nick Konidaris
JCJinhee Chang
Jinhee Chang
ACAaron Chan
Aaron Chan
CHChristine L. Hann
Christine L. Hann
Supplementary Figure S6 shows clonogenic survival of TNIK-high H446 and TNIK-low DMS114 cells treated with vehicle, 0.5 uM cisplatin, 300 nM NCB-0846, or both for 48h before receiving radiation.

2 September 2026
Verified
Other
Open access
DCDipanwita Dutta Chowdhury
Dipanwita Dutta Chowdhury
EIEddie L. Imada
Eddie L. Imada
NKNick Konidaris
Nick Konidaris
JCJinhee Chang
Jinhee Chang
ACAaron Chan
Aaron Chan
CHChristine L. Hann
Christine L. Hann
Supplementary Figure S4 shows long-term cell viability by clonogenic assay showing that TNIK-high SCLC cells (H446) are more sensitive to NCB-0846 (300nM) than TNIK-low SCLC cells (DMS114).